| P2093 | author name string | Thierry Petit | |
| | Xavier Pivot | |
| P2860 | cites work | Trastuzumab emtansine for HER2-positive advanced breast cancer | Q27851917 |
| | Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort | Q33731346 |
| | A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers | Q37099507 |
| | Emilia: use cunning to survive cancer. | Q50146628 |
| | Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer | Q62022868 |
| | Trastuzumab in the treatment of breast cancer | Q81374982 |
| | Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study | Q93138554 |
| P433 | issue | 8 | |
| P304 | page(s) | 1043-1044 | |
| P577 | publication date | 2019-06-27 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | A new agent in the family of antibody-drug conjugates | |
| P478 | volume | 20 | |